MCID: BLM008
MIFTS: 53

Bulimia Nervosa 2

Categories: Genetic diseases, Mental diseases, Neuronal diseases

Aliases & Classifications for Bulimia Nervosa 2

MalaCards integrated aliases for Bulimia Nervosa 2:

Name: Bulimia Nervosa 2 53 71 28
Anorexia Nervosa 53 12 72 51 41 14 69
Anorexia Nervosa, Susceptibility to 53 13
Bulimia Nervosa 41 69
Buln2 53 71
Bulimia Nervosa, Susceptibility to, 2 53
Anorexia Nervosa 2 71
Anon2 71

Classifications:



External Ids:

OMIM 53 610269
Disease Ontology 12 DOID:8689
ICD10 32 F50.0 F50.00
ICD9CM 34 307.1
NCIt 46 C34387

Summaries for Bulimia Nervosa 2

UniProtKB/Swiss-Prot : 71 Anorexia nervosa 2: An eating disorder characterized by the lack or loss of appetite, excess fear of becoming overweight, body image disturbance, significant weight loss, refusal to maintain minimal normal weight, and amenorrhea. Bulimia nervosa 2: A psychiatric disorder characterized by eating an unusually large amount of food in a short period of time, followed by inappropriate acts (purging) to avert weight gain. Compensatory behavior includes self-induced vomiting, laxative abuse, and excessive exercise.

MalaCards based summary : Bulimia Nervosa 2, also known as anorexia nervosa, is related to anorexia nervosa 1 and bulimia nervosa 1, and has symptoms including decrease in appetite An important gene associated with Bulimia Nervosa 2 is BDNF (Brain Derived Neurotrophic Factor), and among its related pathways/superpathways are Peptide ligand-binding receptors and G-Beta Gamma Signaling. The drugs Fluoxetine and Aripiprazole have been mentioned in the context of this disorder. Affiliated tissues include heart, and related phenotypes are behavior/neurological and homeostasis/metabolism

Disease Ontology : 12 An eating disorder characterized by refusal to maintain a healthy body weight, and an obsessive fear of gaining weight due to a distorted self image.

OMIM : 53 For a phenotypic description and a discussion of heterogeneity of susceptibility to bulimia nervosa, see 607499. For a phenotypic description and a discussion of heterogeneity of susceptibility to anorexia nervosa, see 606788. (610269)

Wikipedia : 72 Anorexia nervosa, often referred to simply as anorexia, is an eating disorder characterized by low... more...

Related Diseases for Bulimia Nervosa 2

Diseases in the Bulimia Nervosa 1 family:

Bulimia Nervosa 2

Diseases related to Bulimia Nervosa 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 145)
# Related Disease Score Top Affiliating Genes
1 anorexia nervosa 1 32.9 ANON1 HTR2A
2 bulimia nervosa 1 28.7 BDNF CCK GHRL HTR2A LEP NPY
3 acidophil adenoma 10.5 IGF1 POMC
4 classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency 10.5 LEP POMC
5 abdominal obesity-metabolic syndrome 1 10.4 ADIPOQ GHRL LEP
6 nutritional deficiency disease 10.4 GHRL IGF1 LEP
7 galactorrhea 10.4 IGF1 PRL
8 short bowel syndrome 10.4 CCK IGF1 PYY
9 fasting hypoglycemia 10.4 CRH IGF1 POMC
10 central precocious puberty 10.4 IGF1 LEP
11 ectopic cushing syndrome 10.4 CRH GHRL POMC
12 gastroesophageal reflux 10.4 CCK GHRL PYY
13 persistent fetal circulation syndrome 10.4 CRH IGF1 POMC
14 anovulation 10.3 IGF1 LEP PRL
15 severe pre-eclampsia 10.3 ADIPOQ LEP LEPR
16 craniopharyngioma 10.3 GHRL IGF1 PRL
17 pituitary infarct 10.3 IGF1 POMC PRL
18 stereotypic movement disorder 10.3 CCK NPY PRL
19 central nervous system organ benign neoplasm 10.3 IGF1 POMC PRL
20 hyperinsulinism 10.3 GHRL IGF1 LEP
21 nelson syndrome 10.3 CRH POMC PRL
22 apnea, obstructive sleep 10.2 ADIPOQ HTR2A LEP
23 acth-secreting pituitary adenoma 10.2 CRH POMC PRL
24 gastrointestinal system disease 10.2 CCK CRH GHRL PYY
25 adrenal cortex disease 10.2 CRH POMC PRL
26 adrenal gland disease 10.2 CRH POMC PRL
27 thyroid gland disease 10.2 IGF1 POMC PRL
28 premenstrual tension 10.2 CRH POMC PRL
29 organ system benign neoplasm 10.2 IGF1 POMC PRL
30 pancreas disease 10.2 CCK IGF1 LEP POMC
31 acquired generalized lipodystrophy 10.2 ADIPOQ LEP RETN
32 hyperandrogenism 10.2 IGF1 POMC PRL
33 obesity-hypoventilation syndrome 10.2 ADIPOQ LEP RETN
34 idiopathic recurrent pericarditis 10.2 ADIPOQ LEP RETN
35 cell type benign neoplasm 10.2 IGF1 POMC PRL
36 polycystic ovary syndrome 10.2 GHRL IGF1 LEP PRL
37 sick building syndrome 10.2 LEP POMC
38 multiple symmetrical lipomatosis 10.2 ADIPOQ LEP RETN
39 lutheran suppressor, x-linked 10.2 ADIPOQ LEP RETN
40 chiasmal syndrome 10.2 POMC PRL
41 nonalcoholic steatohepatitis 10.2 ADIPOQ LEP RETN
42 diabetes insipidus 10.2 CRH POMC PRL
43 coronary artery aneurysm 10.2 ADIPOQ LEP RETN
44 carcinoid syndrome 10.1 GHRH IGF1 NPY PYY
45 sheehan syndrome 10.1 CRH IGF1 POMC PRL
46 pituitary apoplexy 10.1 POMC PRL
47 amenorrhea 10.1 CRH LEP POMC PRL
48 sella turcica neoplasm 10.1 GHRH POMC PRL
49 tuberculum sellae meningioma 10.1 GHRH POMC PRL
50 atypical depressive disorder 10.1 CRH SLC6A4

Comorbidity relations with Bulimia Nervosa 2 via Phenotypic Disease Network (PDN):


Acute Cystitis Major Depressive Disorder
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Bulimia Nervosa 2:



Diseases related to Bulimia Nervosa 2

Symptoms & Phenotypes for Bulimia Nervosa 2

Clinical features from OMIM:

610269

UMLS symptoms related to Bulimia Nervosa 2:


decrease in appetite

MGI Mouse Phenotypes related to Bulimia Nervosa 2:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.35 SLC6A4 BDNF CCK CRH GHR GHRL
2 homeostasis/metabolism MP:0005376 10.33 PYY RETN SLC6A4 ADIPOQ AGRP BDNF
3 endocrine/exocrine gland MP:0005379 10.3 ADIPOQ BDNF CCK CRH GHR GHRH
4 adipose tissue MP:0005375 10.27 ADIPOQ AGRP CRH GHR GHRL IGF1
5 growth/size/body region MP:0005378 10.25 ADIPOQ AGRP BDNF CRH GHR GHRH
6 nervous system MP:0003631 10.1 AGRP BDNF CCK CRH GHR GHRH
7 integument MP:0010771 10.07 IGF1 LEP LEPR POMC PRL SLC6A4
8 liver/biliary system MP:0005370 10.06 ADIPOQ AGRP CRH GHR GHRH LEP
9 normal MP:0002873 9.81 AGRP BDNF CRH GHRL IGF1 LEPR
10 renal/urinary system MP:0005367 9.61 ADIPOQ CCK CRH GHR IGF1 LEP
11 skeleton MP:0005390 9.28 ADIPOQ CRH GHR HTR2A IGF1 LEP

Drugs & Therapeutics for Bulimia Nervosa 2

Drugs for Bulimia Nervosa 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 169)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Fluoxetine Approved, Vet_approved Phase 4,Not Applicable 54910-89-3 3386
2
Aripiprazole Approved, Investigational Phase 4,Phase 3 129722-12-9 60795
3
Olanzapine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 132539-06-1 4585
4
Dopamine Approved Phase 4,Not Applicable 51-61-6, 62-31-7 681
5
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
6
Amphetamine Approved, Illicit, Investigational Phase 4 300-62-9 3007 5826
7
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
8 Raclopride Investigational Phase 4,Not Applicable 84225-95-6
9 Antipsychotic Agents Phase 4,Phase 3,Phase 2,Not Applicable
10 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
11 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
12 Neurotransmitter Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
13 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
14
Serotonin Phase 4,Phase 3,Phase 2,Not Applicable 50-67-9 5202
15 Serotonin Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Serotonin Uptake Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
17 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
18 Antidepressive Agents Phase 4,Not Applicable
19 Antidepressive Agents, Second-Generation Phase 4,Not Applicable
20 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Not Applicable
21 Cytochrome P-450 Enzyme Inhibitors Phase 4,Not Applicable
22 Antiemetics Phase 4,Phase 3,Phase 2,Not Applicable
23 Autonomic Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Not Applicable
25 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Not Applicable
26 Dopamine Agents Phase 4,Not Applicable
27 Dopamine Antagonists Phase 4,Not Applicable
28 Serotonin Antagonists Phase 4
29 Adrenergic Agents Phase 4,Not Applicable
30 Central Nervous System Stimulants Phase 4,Not Applicable
31 Dopamine Uptake Inhibitors Phase 4,Not Applicable
32
Teriparatide Approved, Investigational Phase 3,Phase 2 52232-67-4 16133850
33
Estradiol Approved, Investigational, Vet_approved Phase 2, Phase 3, Phase 1 50-28-2 5757
34
Ethinyl Estradiol Approved Phase 2, Phase 3 57-63-6 5991
35
Medroxyprogesterone acetate Approved, Investigational Phase 2, Phase 3,Phase 1 71-58-9
36
Progesterone Approved, Vet_approved Phase 2, Phase 3 57-83-0 5994
37
Epinephrine Approved, Vet_approved Phase 2, Phase 3 51-43-4 5816
38
Levonorgestrel Approved, Investigational Phase 2, Phase 3 797-63-7, 17489-40-6 13109
39 Racepinephrine Approved Phase 2, Phase 3 329-65-7
40
Etidronic acid Approved Phase 2, Phase 3,Not Applicable 2809-21-4, 7414-83-7 3305
41
Methyltestosterone Approved Phase 2, Phase 3,Not Applicable 58-18-4 6010
42
Testosterone Approved, Investigational Phase 2, Phase 3,Not Applicable 58-22-0 6013
43
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078 2978
44
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
45
Denosumab Approved Phase 3,Early Phase 1 615258-40-7
46
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 2, Phase 3 53-43-0 9860744
47 tannic acid Approved, Nutraceutical Phase 3
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
49 Bone Density Conservation Agents Phase 3,Phase 2,Not Applicable,Early Phase 1
50 Vitamins Phase 3

Interventional clinical trials:

(show top 50) (show all 207)

# Name Status NCT ID Phase Drugs
1 Olanzapine in the Treatment of Anorexia Nervosa Completed NCT00592930 Phase 4 olanzapine;placebo
2 A Double-blind, Placebo Controlled Trial of Risperidone for the Treatment of Anorexia Nervosa Completed NCT00140426 Phase 4 Risperidone;Placebo
3 Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa Completed NCT00288574 Phase 4 Fluoxetine;Placebo
4 Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa Completed NCT00685334 Phase 4 Olanzapine;Aripiprazole
5 Monoamine Contributions to Neurocircuitry in Eating Disorders Completed NCT02020408 Phase 4 [11C]raclopride;[11C]DASB;amphetamine
6 Does Hydroxyzine Decrease Anxiety in Underweight Patients Diagnosed With an Eating Disorder Withdrawn NCT01372670 Phase 4 Hydroxyzine;hydroxyzine HCL
7 ARIpiprazole in Anorexia NErvosa Unknown status NCT01082848 Phase 3 aripiprazole;placebo
8 The Efficacy of Readiness and Motivation Therapy in Individuals With Anorexia Nervosa and Bulimia Nervosa Unknown status NCT00220662 Phase 3
9 A Pilot Study to Evaluate the Effect of Forsteo (Teriparatide, 1-34-rh-PTH) in Anorexia Nervosa Patients With Low Bone Mineral Density and Increased Bone Fagility (FAN-Trial) Unknown status NCT01801397 Phase 3 osteoanabolic therapy
10 Influence of Protein Supplements on Serum Insulin-like Growth Factor-I Levels in Women With Anorexia Nervosa Completed NCT01823822 Phase 2, Phase 3
11 Effects of Anorexia Nervosa on Bone Mass in Adolescents Completed NCT00088153 Phase 2, Phase 3 Physiologic Estrogen/progesterone
12 Comparison of Two Types of Family Therapy in the Treatment of Adolescent Anorexia Nervosa Completed NCT00610753 Phase 3
13 The Role of Lactobacillus Reuteri in Children and Adolescents With Anorexia Nervosa Completed NCT02004288 Phase 2, Phase 3
14 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa Completed NCT00310791 Phase 2, Phase 3 Hormone replacement therapy (estrogen/progestin);Dehydroepiandrosterone (DHEA)
15 Bone Loss in Women With Anorexia Nervosa Completed NCT00089843 Phase 2, Phase 3 Testosterone;Actonel (risedronate);Placebo Actonel (risedronate);Placebo testosterone
16 Cannabinoid Receptor (CB1) Agonist Treatment in Severe Chronic Anorexia Nervosa Completed NCT00760695 Phase 3 dronabinol;placebo
17 Hormonal Therapy for Teens With Anorexia Nervosa Completed NCT01343771 Phase 3 DHEA (Prasterone) + ERT (Aviane)
18 Effects of Anorexia Nervosa on Peak Bone Mass Recruiting NCT01301183 Phase 3 RhIGF-1 with transdermal 17-beta estradiol;Placebo and transdermal 17-beta estradiol
19 Impact of Denosumab in the Prevention of Bone Loss in Non-menopausal Women With Anorexia Nervosa Recruiting NCT02567279 Phase 3 Denosumab subcutaneous injections;Placebo subcutaneous injections
20 Severe Decrease of Growth Velocity in Children With Anorexia Nervosa.Therapeutic Trial of Growth Hormone Active, not recruiting NCT01626833 Phase 2, Phase 3 SOMATROPINE* : Norditropine® simplexx®
21 Evaluation of the Efficacy and Safety of Olanzapine for Anorexia Nervosa in Children and Adolescents Terminated NCT01184443 Phase 3 Olanzapine
22 Fatty Acids Omega -3 Diet Supplementation Efficiency and Safety Evaluation in Anorexia Nervosa Unknown status NCT01761942 Phase 2
23 Treatment of Anxiety and Anorexia Nervosa in Adolescents Unknown status NCT01933243 Phase 2 Fish oil;Placebo pill
24 Dissonance Inpatient Relapse Prevention Program for Anorexia Nervosa Unknown status NCT01611220 Phase 2
25 Therapeutic Effects of Neurofeedback in Anorexia Nervosa Completed NCT01390493 Phase 1, Phase 2
26 Phase 2 Pilot Study to Evaluate the Safety and Efficacy of RM-131 Administered to Females With Anorexia Nervosa Completed NCT01642550 Phase 2 RM-131;Placebo
27 A Relapse Prevention Program for Reducing Relapse and Fear of Food in People With Anorexia Nervosa Completed NCT00627341 Phase 1, Phase 2
28 Treatment for Young Adults With Anorexia Nervosa Completed NCT01190423 Phase 1, Phase 2
29 The Role of Parathyroid Hormone (PTH) in Low Bone Mass in Anorexia Nervosa Completed NCT00759772 Phase 2 Placebo;Teriparatide
30 Olanzapine in the Treatment of Patients With Anorexia Nervosa Completed NCT00260962 Phase 2 Olanzapine
31 Effectiveness of Olanzapine Versus Placebo in Treating Outpatients With Anorexia Nervosa Completed NCT00692185 Phase 2 Olanzapine;Placebo
32 Effects of rhIGF-1 on Bone Metabolism in Adolescent Girls With Anorexia Nervosa Completed NCT00720122 Phase 2 Recombinant human insulin like growth factor-1 (rhIGF-1)
33 Hormonal Factors in the Treatment of Anorexia Nervosa Completed NCT01121211 Phase 2 Testosterone;Placebo
34 Comparing the Effectiveness of Three Types of Therapy for the Treatment of Anorexia Nervosa in Adolescents Completed NCT00183586 Phase 2
35 Effect of Growth Hormone on Bone Metabolism in Anorexia Nervosa Completed NCT00283595 Phase 2 Recombinant Human Growth Hormone;Placebo for Recombinant Human Growth Hormone
36 The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa Completed NCT00320567 Phase 2 norgestimate/ethinyl estradiol
37 Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents Completed NCT00516386 Phase 1, Phase 2 RhIGF-1
38 Amino Acids, Serotonin, and Body Weight Regulation Completed NCT00343928 Phase 2
39 Transdermal Estrogen in Older Premenopausal Women With Anorexia Nervosa Recruiting NCT02475265 Phase 2 estradiol 0.045 mg/levonorgestrel 0.015mg
40 Estrogen Replacement in Anorexia Nervosa Recruiting NCT03172533 Phase 2 ethinyl estradiol 0.03mg and dienogest 2 mg (combination);Placebo oral capsule
41 A Double Blind, Placebo Controlled Trial of Quetiapine in Anorexia Nervosa, a Dual Site Study Terminated NCT00584688 Phase 2 quetiapine
42 The Effect of Testosterone Replacement on Bone Mineral Density in Boys and Men With Anorexia Nervosa Withdrawn NCT00853502 Phase 2 testosterone cypionate
43 Look at Food and Lose Your Fear - Evaluation of a Computerized Attention Training (CAT) for Anorexia Nervosa Patients Unknown status NCT02484599 Phase 1
44 Deep Brain Stimulation for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01476540 Phase 1
45 Funen Anorexia Nervosa Study - Retrospective Cohort Study and 10 Year Follow-up Study Unknown status NCT00267228 Phase 1
46 Deep Brain Stimulation and Capsulotomy for the Treatment of Refractory Anorexia Nervosa Unknown status NCT01678014 Phase 1
47 Yoga in Treatment of Eating Disorders Unknown status NCT00870753 Phase 1
48 Effectiveness of Cognitive Remediation Therapy in Improving Treatment Retention in People With Anorexia Nervosa Completed NCT00601822 Phase 1
49 Family Treatment for Adolescents With Anorexia Nervosa Completed NCT01280799 Phase 1
50 Effectiveness of Family-Based Versus Individual Psychotherapy in Treating Adolescents With Anorexia Nervosa Completed NCT00149786 Phase 1

Search NIH Clinical Center for Bulimia Nervosa 2

Cochrane evidence based reviews: bulimia nervosa

Genetic Tests for Bulimia Nervosa 2

Genetic tests related to Bulimia Nervosa 2:

# Genetic test Affiliating Genes
1 Bulimia Nervosa 2 28 BDNF

Anatomical Context for Bulimia Nervosa 2

MalaCards organs/tissues related to Bulimia Nervosa 2:

38
Heart

Publications for Bulimia Nervosa 2

Articles related to Bulimia Nervosa 2:

(show top 50) (show all 1371)
# Title Authors Year
1
Variation in reproductive outcomes of women with histories of bulimia nervosa, anorexia nervosa, or eating disorder not otherwise specified relative to the general population and closest-aged sisters. ( 29331083 )
2018
2
The Impact of Alexithymia on Emotion Dysregulation in Anorexia Nervosa and Bulimia Nervosa over Time. ( 29266572 )
2018
3
Ammonium acid urate urolithiasis in anorexia nervosa: a case report and literature review. ( 28469876 )
2017
4
Heightened Olfactory Sensitivity in Young Females with Recent-Onset Anorexia Nervosa and Recovered Individuals. ( 28060877 )
2017
5
Modeling anorexia nervosa: transcriptional insights from human iPSC-derived neurons. ( 28291261 )
2017
6
Acute retropharyngeal abscess in a patient with anorexia nervosa. ( 28058633 )
2017
7
Anorexia nervosa and bulimia nervosa: A meta-analysis of executive functioning. ( 28851577 )
2017
8
Transition Care in Anorexia Nervosa Through Guidance Online from Peer and Carer Expertise (TRIANGLE): Study Protocol for a Randomised Controlled Trial. ( 28944595 )
2017
9
Symptom trajectories throughout two family therapy treatments for adolescent anorexia nervosa. ( 28913833 )
2017
10
Bone metabolism in anorexia nervosa and hypothalamic amenorrhea. ( 29107598 )
2017
11
Significant Locus and Metabolic Genetic Correlations Revealed in Genome-Wide Association Study of Anorexia Nervosa. ( 28494655 )
2017
12
Plasma BDNF levels and anxiety in women with recovery from anorexia nervosa. ( 28522315 )
2017
13
Huge pericardial effusion with subcutaneous emphysema, pneumomediastinum and pneumopericardium in anorexia nervosa. ( 28799456 )
2017
14
Anorexia nervosa of the restrictive type and celiac disease in adolescence. ( 28496327 )
2017
15
Molecular bases of anorexia nervosa, bulimia nervosa and binge eating disorder: shedding light on the darkness. ( 28762842 )
2017
16
Outcomes of an inpatient refeeding protocol in youth with anorexia nervosa: Rady Children's Hospital San Diego/University of California, San Diego. ( 28053702 )
2017
17
Membranous tracheal stenosis in a patient with anorexia nervosa and self-induced vomiting- challenges in securing the airway. ( 28377879 )
2017
18
Long-Term Follow-up Study of MRI-Guided Bilateral Anterior Capsulotomy in Patients With Refractory Anorexia Nervosa. ( 28945886 )
2017
19
Treatment of Anorexia Nervosa: The Importance of Disease Progression in the Prognosis. ( 28926324 )
2017
20
Geriatric Anorexia Nervosa. ( 28923819 )
2017
21
The role of pride in women with anorexia nervosa: A grounded theory study. ( 28467686 )
2017
22
Risk of being convicted of theft and other crimes in anorexia nervosa and bulimia nervosa: A prospective cohort study in a Swedish female population. ( 28791709 )
2017
23
Anorexia nervosa complicated with hiatal hernia and superior mesenteric artery syndrome: A case illustrating the risk of inference observation confusion. ( 29264011 )
2017
24
An Adolescent Male With Anorexia Nervosa Favorably Responded to Mirtazapine. ( 28504977 )
2017
25
Influence of visceral interoceptive experience on the brain's response to food images in anorexia nervosa. ( 28498277 )
2017
26
Adequacy of nutrient intake in women with restrictive anorexia nervosa. ( 28526387 )
2017
27
Personalized polyunsaturated fatty acids as a potential adjunctive treatment for anorexia nervosa. ( 28873340 )
2017
28
Fifty years of anorexia nervosa and other eating disorders in the Australian & New Zealand Journal of Psychiatry. ( 28521537 )
2017
29
Computerized assessment of body image in anorexia nervosa and bulimia nervosa: comparison with standardized body image assessment tool. ( 27796596 )
2017
30
Themes arising in clinical consultation for therapists implementing family-based treatment for adolescents with anorexia nervosa: a qualitative study. ( 28878927 )
2017
31
A dark past, a restrained present, and an apocalyptic future: time perspective, personality, and life satisfaction among anorexia nervosa patients. ( 28929023 )
2017
32
Lesson of the month 2: A choroid plexus papilloma manifesting as anorexia nervosa in an adult. ( 28365635 )
2017
33
Hepatic Complications of Anorexia Nervosa. ( 28932925 )
2017
34
Relationship of body weight with gastrointestinal motor and sensory function: studies in anorexia nervosa and obesity. ( 28056812 )
2017
35
Comparing effects: a reanalysis of two studies on season of birth bias in anorexia nervosa. ( 28078085 )
2017
36
Metasynthesis of the Views about Treatment of Anorexia Nervosa in Adolescents: Perspectives of Adolescents, Parents, and Professionals. ( 28056106 )
2017
37
Food portion size area mediates energy effects on expected anxiety in anorexia nervosa. ( 28089925 )
2017
38
Treatment with granulocyte colony-stimulating factor in the refeeding phase of anorexia nervosa complicated with severe neutropenia and sepsis: a case report. ( 28871553 )
2017
39
A child with anorexia nervosa presenting with severe infection with cytopenia and hemophagocytosis: a case report. ( 28878816 )
2017
40
Differences in Neural Responses to Reward and Punishment Processing between Anorexia Nervosa Subtypes: An fMRI Study. ( 28459134 )
2017
41
Anorexia nervosa and childhood sexual abuse: Treatment outcomes of intensive enhanced cognitive behavioural therapy. ( 28927864 )
2017
42
Advances in the treatment of anorexia nervosa: a review of established and emerging interventions. ( 28889819 )
2017
43
Genetics of Anorexia Nervosa. ( 28940168 )
2017
44
The association between symptoms of autism and neuropsychological performance in females with Anorexia Nervosa. ( 28923433 )
2017
45
Ehlers-Danlos syndrome in a young woman with anorexia nervosa and complex somatic symptoms. ( 29247552 )
2017
46
Reexamining the Role of Electroconvulsive Therapy in Anorexia Nervosa in Adolescents. ( 28471772 )
2017
47
Depictive and metric body size estimation in anorexia nervosa and bulimia nervosa: A systematic review and meta-analysis. ( 28818670 )
2017
48
Serum kisspeptin concentrations are negatively correlated with body mass index in adolescents with anorexia nervosa and amenorrhea. ( 28500826 )
2017
49
A focus on reward in anorexia nervosa through the lens of the activity-based anorexia (ABA) rodent model. ( 28475260 )
2017
50
Manifestation of hyperaldosteronism related hypokalemia in a case of anorexia nervosa. ( 28962826 )
2017

Variations for Bulimia Nervosa 2

ClinVar genetic disease variations for Bulimia Nervosa 2:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 BDNF NM_170735.5(BDNF): c.196G> A (p.Val66Met) single nucleotide variant protective,risk factor rs6265 GRCh37 Chromosome 11, 27679916: 27679916

Expression for Bulimia Nervosa 2

Search GEO for disease gene expression data for Bulimia Nervosa 2.

Pathways for Bulimia Nervosa 2

Pathways related to Bulimia Nervosa 2 according to GeneCards Suite gene sharing:

(show all 16)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 CCK CRH GH1 GHR GHRH GHRL
2
Show member pathways
12.86 BDNF CRH GH1 GHRH HTR2A POMC
3
Show member pathways
12.3 GH1 LEP LEPR PRL
4
Show member pathways
12.24 ADIPOQ IGF1 LEP LEPR
5
Show member pathways
12.1 GH1 GHR LEP LEPR PRL
6
Show member pathways
12.03 GH1 GHRL IGF1 LEP POMC
8 11.78 ADIPOQ GH1 IGF1 LEP RETN
9 11.69 ADIPOQ IGF1 LEP
10 11.48 GH1 GHR IGF1
11 11.33 LEP LEPR PRL
12
Show member pathways
11.22 GH1 GHR PRL
13
Show member pathways
11.06 LEP LEPR POMC
14 10.94 ADIPOQ AGRP LEP LEPR NPY POMC
15 10.79 AGRP POMC
16 10.32 CRH POMC

GO Terms for Bulimia Nervosa 2

Cellular components related to Bulimia Nervosa 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.8 ADIPOQ AGRP CCK CRH GH1 GHR
2 neuronal cell body GO:0043025 9.65 AGRP CCK CRH GHR HTR2A
3 extracellular region GO:0005576 9.55 ADIPOQ AGRP BDNF CCK CRH GH1
4 endosome lumen GO:0031904 9.32 GH1 PRL
5 growth hormone receptor complex GO:0070195 9.16 GH1 GHR

Biological processes related to Bulimia Nervosa 2 according to GeneCards Suite gene sharing:

(show all 48)
# Name GO ID Score Top Affiliating Genes
1 response to estradiol GO:0032355 9.88 GH1 LEP SLC6A4
2 female pregnancy GO:0007565 9.87 CRH LEP PRL
3 response to nutrient GO:0007584 9.86 ADIPOQ LEP SLC6A4
4 movement of cell or subcellular component GO:0006928 9.86 IGF1 NPY PYY
5 response to insulin GO:0032868 9.85 AGRP LEP RETN
6 neuropeptide signaling pathway GO:0007218 9.84 AGRP NPY POMC PYY
7 regulation of blood pressure GO:0008217 9.83 LEP NPY POMC
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.83 GH1 IGF1 LEP
9 glucose metabolic process GO:0006006 9.83 ADIPOQ GHRL LEP
10 glucose homeostasis GO:0042593 9.83 ADIPOQ LEP LEPR POMC
11 response to nutrient levels GO:0031667 9.8 ADIPOQ GHRL LEP
12 feeding behavior GO:0007631 9.79 AGRP NPY PYY
13 circadian rhythm GO:0007623 9.78 ADIPOQ AGRP LEP SLC6A4
14 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.76 GH1 GHR IGF1 LEP
15 hormone-mediated signaling pathway GO:0009755 9.74 AGRP GHR GHRL
16 regulation of multicellular organism growth GO:0040014 9.73 GHR IGF1 PRL
17 eating behavior GO:0042755 9.72 AGRP CCK LEP
18 energy reserve metabolic process GO:0006112 9.7 LEP LEPR
19 insulin-like growth factor receptor signaling pathway GO:0048009 9.7 GHR IGF1
20 negative regulation of gluconeogenesis GO:0045721 9.69 ADIPOQ LEPR
21 central nervous system neuron development GO:0021954 9.69 LEP NPY
22 behavior GO:0007610 9.69 HTR2A NPY
23 regulation of feeding behavior GO:0060259 9.68 AGRP LEPR
24 sexual reproduction GO:0019953 9.68 LEP LEPR
25 leptin-mediated signaling pathway GO:0033210 9.67 LEP LEPR
26 positive regulation of growth hormone secretion GO:0060124 9.67 GHRH GHRL
27 negative regulation of appetite GO:0032099 9.66 CCK LEP
28 growth hormone receptor signaling pathway GO:0060396 9.65 GH1 GHR
29 growth hormone secretion GO:0030252 9.64 GHRH GHRL
30 positive regulation of feeding behavior GO:2000253 9.64 AGRP GHRL
31 regulation of bone remodeling GO:0046850 9.63 LEP LEPR
32 positive regulation of corticotropin secretion GO:0051461 9.62 CRH GHRL
33 bone mineralization involved in bone maturation GO:0035630 9.62 IGF1 LEP
34 positive regulation of multicellular organism growth GO:0040018 9.62 GH1 GHR GHRH GHRL
35 positive regulation of appetite GO:0032100 9.61 GHRL NPY
36 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.61 GH1 GHR PRL
37 positive regulation of cortisol secretion GO:0051464 9.6 CRH GHRL
38 negative regulation of glucagon secretion GO:0070093 9.58 CRH LEP
39 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.58 GH1 GHRH IGF1
40 positive regulation of JAK-STAT cascade GO:0046427 9.56 GH1 GHR LEP PRL
41 regulation of appetite GO:0032098 9.54 NPY POMC PYY
42 negative regulation of circadian sleep/wake cycle, REM sleep GO:0042322 9.51 CRH GHRL
43 bone growth GO:0098868 9.49 LEP LEPR
44 regulation of receptor activity GO:0010469 9.47 ADIPOQ AGRP BDNF CCK GH1 GHRH
45 adult feeding behavior GO:0008343 9.46 AGRP GHRL LEP NPY
46 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.43 ADIPOQ CCK GH1 GHR HTR2A IGF1
47 G-protein coupled receptor signaling pathway GO:0007186 10.18 CCK CRH GHRH GHRL HTR2A NPY
48 positive regulation of cell proliferation GO:0008284 10.07 CCK CRH GHRH HTR2A IGF1 LEP

Molecular functions related to Bulimia Nervosa 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor binding GO:0005102 9.73 ADIPOQ AGRP CRH LEP NPY POMC
2 growth factor activity GO:0008083 9.71 BDNF GH1 IGF1 LEP
3 G-protein coupled receptor binding GO:0001664 9.46 GHRL NPY POMC PYY
4 neuropeptide hormone activity GO:0005184 9.43 AGRP CCK CRH NPY POMC PYY
5 hormone activity GO:0005179 9.4 ADIPOQ CCK CRH GH1 GHRL IGF1
6 prolactin receptor binding GO:0005148 9.37 GH1 PRL
7 growth hormone-releasing hormone activity GO:0016608 9.32 GHRH GHRL

Sources for Bulimia Nervosa 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....